The 30-year-old program that allows hospitals to buy drugs directly from manufacturers to avoid inflated prices, 340B, cost providers $43.9 billion in 2021, according to HHS’ Health Resources and Services Administration.
Read the full post on Becker's Hospital Review - Healthcare News
